ObvioHealth, Oracle Partnering on APAC Decentralized Clinical Trials

ObvioHealth is joining forces with Oracle in Asia Pacific to get breakthrough therapies to market faster through more efficient integration of diverse data sets. The alliance will enable the rapid collection, integration and analysis of multi-source data collected from sites, patients, devices and labs.
 
“Because DCTs are designed to be more convenient for patients, they naturally involve more complex sources of data—physical sites, electronic health records, wearables, and mobile apps—and Oracle’s technology provides us with a unified environment to bring all of that data together in one place,” ObvioHealth CEO Ivan Jarry said. “The Oracle collaboration will allow us to integrate with more complex and diverse data sets.”
 
This announcement follows ObvioHealth’s launch of ObvioGo, a next-generation decentralized clinical trial (DCT) platform and mobile app. The platform’s eConsent, eCOA, and ePRO capabilities will fully integrate into the Oracle Clinical One Cloud Service (Clinical One), facilitating pharma-grade analytics and reporting that can deliver more timely patient insights. Sponsors benefit from the ObvioGo platform’s device integrations alongside Oracle Clinical One’s robust data management capabilities. And sites familiar with Oracle’s systems can integrate decentralized trial components within their existing workflows. 
 
“Access to data is the cornerstone of moving therapies from clinical trials to available therapies, and trial sponsors in APAC are increasingly looking to more decentralized models to be able to increase trial equity, access, and data availability,” said Henry McNamara, senior vice president and general manager at Oracle Health Sciences. “ObvioHealth has valuable industry experience in conducting these DCT trials in this market. By integrating ObvioHealth’s experience with our centralized capabilities, we’re helping reduce costs, accelerate timelines, and increase the depth of data insights for trials in the region.”
 
An Oracle provider in Asia Pacific, ObvioHealth is one of the first DCT players to conduct fully virtual studies in the region. In addition to its New York headquarters, the company has offices in Singapore, Australia, and Europe. The VRO is also partnered with Novotech, an Asia-Pacific biotech specialist contract research organization.
 
ObvioHealth is an end-to-end virtual research organization (VRO) that delivers better data to sponsors and an easier clinical trial experience for participants. The company developed and launched one of the first patient-centric apps downloadable on smartphones, enabling people to participate in clinical trials from their homes. In the five years since that launch, the company has been awarded 46 studies from 28 blue chip clients, implemented in 28 countries, across 18 different therapeutic areas.